IPO
Regenerative medicine company Orthocell Limited is pleased to announce that it has received firm commitments for a A$10.6m placement (“Placement”) from professional and sophisticated investors, including existing shareholders providing $10m net of expenses.
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Probiodrug AG, announces that its shareholders approved all resolutions proposed by the Company’s Management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, May 29, 2019
Upon approval by the shareholders, ASIT biotech expects to raise between €9M and €12M of convertible notes to finance its focused development
The company’s board of directors hasn’t made a final decision to proceed with the listing.
Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.
MorphoSys AG will present at the following conferences
Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.
ADL Bionatur Solutions recently reported Q119 results, showing positive €0.11m EBITDA, and over 134% year-on-year revenue growth to €10m, driven by 180% growth in contract manufacturing.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces it will be hosting a Capital Markets Day for all investors on Wednesday 12 June 2019.
PRESS RELEASES